SCHEMBL3335920

SCHEMBL3335920

O=C(NNc1nc(-c2ccc([N+](=O)[O-])cc2)cs1)c1ccc(F)cc1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.71
GAA P10253 8/20 0.71
KDM4E B2RXH2 6/20 0.71
MEN1 O00255 6/20 0.71
KMT2A Q03164 6/20 0.71
ALDH1A1 P00352 5/20 0.71
HTT P42858 5/20 0.71
LMNA P02545 5/20 0.71
TDP1 Q9NUW8 4/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
RAB9A P51151 3/20 0.58
CA12 O43570 1/20 0.57
CA9 Q16790 1/20 0.57
NPC1 O15118 1/20 0.56
MAPK1 P28482 1/20 0.56
GFER P55789 1/20 0.52
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3342093 0.89 MAPT (0.72) MAPTGAAKDM4EMEN1KMT2A
SCHEMBL3337680 0.84 CA12 (0.62) MAPTGAAKDM4EMEN1KMT2A
SCHEMBL3340070 0.84 MAPT (0.78) MAPTGAAKDM4EMEN1KMT2A
SCHEMBL3343782 0.84 MAPT (0.78) MAPTGAAKDM4EMEN1KMT2A
SCHEMBL3344724 0.83 KDM4E (1.00) MAPTGAAKDM4EMEN1KMT2A
SCHEMBL3344402 0.82 MAPT (0.66) MAPTGAAKDM4EMEN1KMT2A
SCHEMBL3337733 0.81 RAB9A (0.77) MAPTGAAKDM4EMEN1KMT2A
SCHEMBL3341533 0.81 CA12 (0.54) MAPTGAAKDM4EMEN1KMT2A
SCHEMBL30360026 0.80 KDM4E (0.53) MAPTGAAKDM4EMEN1KMT2A
SCHEMBL3341971 0.79 CA12 (0.50) MAPTGAAKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US claimed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885GAA 76/4885KDM4E 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.